"We are no longer in Valeant," Steven Einhorn said at the Reuters Global Investment Outlook Summit in New York. "We sold at higher prices." He did not say exactly when Omega exited its position. Valeant's stock price has cratered in the last two months amid questions about the company's drug pricing and business and accounting practices. The shares have tumbled 48 percent so far this year and wrecked many hedge funds' annual performance numbers. William Ackman's Pershing Square Holdings portfolio, which is one of the top five holders of Valeant, has lost 21 percent this year through Nov. 10. Hedge...